AI assistant
Sending…
Qualigen Therapeutics, Inc. — Director's Dealing 2016
Dec 1, 2016
35251_dirs_2016-11-30_e2ab19a9-d4ae-4a1d-9b5e-fccc4373759f.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: RITTER PHARMACEUTICALS INC (RTTR)
CIK: 0001460702
Period of Report: 2016-11-29
Reporting Person: PROEHL GERALD T (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2016-11-29 | Stock Option (2015 Equity Incentive Plan) | $2.37 | A | 7000 | Acquired | 2026-11-29 | Common Stock (7000) | Direct |
Footnotes
F1: Of the 7,000 shares granted, 730 shares were vested as of the grant date and the remaining 6,270 shares will vest ratably over the next 43 months.
More from Qualigen Therapeutics, Inc.
Board/Management Information
2026
May 28
Capital/Financing Update
2026
May 14
Annual Report
2026
Mar 30
Regulatory Filings
2026
Feb 27
Board/Management Information
2026
Feb 17
Regulatory Filings
2026
Feb 2
Major Shareholding Notification
2026
Jan 29
Declaration of Voting Results & Voting Rights Announcements
2026
Jan 6
Audit Report / Information
2025
Dec 16
Proxy Solicitation & Information Statement
2025
Dec 15